ideal
vaccin
would
elicit
exact
immun
respons
occur
natur
infect
highli
pathogen
influenza
viru
express
influenza
viru
protein
live
replic
vector
safe
induc
strong
humor
cellular
immun
respons
compar
natur
infect
souza
et
al
recombin
vector
develop
consid
danger
vaccin
peopl
even
vastli
attenu
form
danger
virus
highli
pathogen
influenza
viru
ebola
viru
vaccin
recombin
vector
offer
sever
advantag
vaccin
inactiv
influenza
virus
inactiv
vaccin
induc
shortliv
antibodymedi
immun
recombin
vector
elicit
longerlast
immun
respons
stimul
memori
b
cell
also
manufactur
recombin
vaccin
entail
substanti
less
risk
grow
larg
quantiti
influenza
virus
express
highli
pathogen
hemagglutinin
ha
neuraminidas
na
protein
requir
inactiv
sinc
recombin
vector
caus
influenza
mani
differ
virus
bacteria
current
test
abil
function
good
recombin
vector
good
vector
easi
manipul
genet
allow
insert
larg
foreign
gene
epitop
vector
grow
well
easi
produc
largescal
oper
foreign
protein
highli
express
vector
elicit
best
immun
respons
protein
vector
elicit
strong
immun
respons
may
interfer
induct
respons
foreign
protein
also
reduc
effect
boost
initi
vaccin
express
foreign
protein
host
transient
vector
must
fulli
clear
host
adapt
immun
respons
commenc
integr
dna
vector
host
genom
must
occur
disrupt
host
gene
possibl
lead
develop
cancer
human
preexist
antibodi
vector
could
prevent
replic
vector
subsequ
prevent
induct
immun
respons
foreign
protein
ideal
vector
caus
diseas
symptom
human
safe
even
immunocompromis
individu
young
children
addit
recombin
vector
requir
refriger
would
facilit
distribut
vaccin
develop
nation
recombin
vector
administ
without
needl
would
also
aid
distribut
enhanc
vaccin
complianc
babiuk
tikoo
barouch
nabel
souza
et
al
barouch
li
et
al
sever
virus
possess
mani
characterist
use
vector
newcastl
diseas
viru
ndv
contain
nonseg
singlestrand
negativesens
rna
genom
belong
famili
paramyxovirida
ndv
contain
six
gene
encod
seven
protein
nucleocapsid
protein
np
phosphoprotein
v
protein
pv
matrix
protein
fusion
f
protein
hemagglutininneuraminidas
hn
larg
polymeras
l
protein
viral
polymeras
disassoci
viral
genom
transcript
gene
express
level
protein
reduc
sequenti
manner
end
genom
thu
express
level
foreign
protein
control
posit
viral
genom
huang
et
al
ndv
natur
infect
avian
speci
highli
contagi
viru
pathogen
rang
avirul
high
level
mortal
huang
et
al
one
determin
ndv
pathogen
cleavag
site
f
protein
necessari
fusion
viral
envelop
cell
membran
ndv
strain
contain
f
protein
cleavag
site
sever
basic
amino
acid
readili
cleav
numer
cellular
proteas
varieti
tissu
lead
wide
dissemin
viru
throughout
host
organ
high
virul
ndv
strain
contain
f
protein
cleavag
site
contain
fewer
basic
amino
acid
cleav
secret
proteas
found
lung
thu
tropism
limit
lung
lead
lower
pathogen
panda
et
al
abil
easili
adjust
pathogen
ndv
one
reason
ndv
attract
recombin
vector
ndv
possess
mani
qualiti
ideal
vector
use
human
sever
properti
make
specif
suit
recombin
vector
pandem
influenza
sinc
natur
condit
ndv
infect
bird
human
preexist
immun
ndv
preexist
antibodi
recombin
vector
drastic
reduc
complet
elimin
format
immun
foreign
protein
express
vector
one
major
reason
recombin
vector
effect
fact
bird
major
reservoir
ndv
highli
pathogen
avian
influenza
viru
hpai
led
develop
dual
vaccin
protect
poultri
diseas
ndv
viru
express
influenza
viru
ha
first
rescu
nakaya
et
al
influenza
viru
ha
gene
viru
insert
p
gene
hitchner
strain
avirul
viru
use
live
vaccin
bird
russel
ezeifeka
genom
structur
recombin
ndv
illustr
fig
influenza
viru
ha
confirm
incorpor
viral
envelop
cleav
show
pathogen
embryon
chicken
egg
use
grow
larg
stock
influenza
viru
ndv
vaccin
importantli
vaccin
mice
confer
complet
protect
lethal
challeng
influenza
viru
nakaya
et
al
recent
ndv
recombin
vector
express
ha
gene
hpai
strain
also
gener
ndv
express
influenza
viru
strain
caus
ill
death
human
work
infect
bird
design
dual
vaccin
protect
bird
hpai
ndv
park
et
al
veit
et
al
ge
et
al
order
enhanc
incorpor
viral
envelop
ectodomain
fuse
transmembran
cytoplasm
domain
f
gene
insert
ndv
genom
p
gene
viru
attenu
confer
full
protect
challeng
hpai
three
basic
amino
acid
ad
f
protein
fusion
site
enhanc
viral
spread
result
viru
still
highli
attenu
compar
pathogen
strain
ndv
induc
protect
stringent
challeng
hpai
protect
challeng
ndv
park
et
al
clone
differ
nonpathogen
ndv
strain
la
sota
use
vaccin
chicken
chicken
fulli
protect
lethal
challeng
hpai
ndv
vaccin
also
prevent
chicken
shed
viru
challeng
veit
et
al
ge
et
al
ndv
also
use
recombin
vector
pathogen
influenza
viru
infecti
bursal
diseas
viru
ibdv
caus
immunosuppress
poultri
reduc
effect
vaccin
leav
anim
especi
suscept
infect
recombin
ndv
express
ibdv
protein
provid
protect
ibdv
ndv
chicken
huang
et
al
anoth
recombin
ndv
design
prevent
respiratori
syncyti
viru
rsv
caus
sever
respiratori
diseas
infant
elderli
recombin
ndv
express
rsv
f
protein
protect
mice
challeng
rsv
martinezsobrido
et
al
recombin
ndv
vaccin
pathogen
sever
acut
respiratori
syndrom
viru
sarscov
human
parainfluenza
viru
type
test
primat
sarscov
caus
worldwid
outbreak
mortal
rate
vaccin
african
green
monkey
ndv
vector
express
sarscov
spike
protein
result
dramat
reduct
viral
replic
challeng
sarscov
dinapoli
et
al
ndv
vector
express
hn
protein
induc
level
antibodi
compar
natur
infect
african
green
monkey
bukreyev
et
al
one
limit
ndv
recombin
vector
difficult
grow
ndv
long
foreign
gene
multipl
foreign
gene
insert
ndv
genom
shortcom
recent
overcom
rescu
recombin
ndv
biseg
genom
one
segment
contain
gene
np
p
l
segment
contain
gene
f
hn
recombin
viru
express
gfp
first
segment
sarscov
spike
protein
second
segment
rescu
demonstr
ndv
design
express
multipl
foreign
protein
larg
protein
sarscov
spike
protein
fig
gao
et
al
interestingli
ndv
test
recombin
vector
infecti
diseas
also
cancer
previous
observ
ndv
replic
human
tumor
cell
much
readili
normal
cell
believ
occur
cancer
cell
often
mutat
interferon
pathway
key
host
antivir
immun
respons
normal
cell
intact
interferon
pathway
sinc
ndv
sensit
effect
interferon
rapidli
elimin
normal
cell
cancer
cell
howev
kill
ndv
sinc
mount
antivir
respons
ndv
vector
express
granulocytemacrophag
colonystimul
factor
gmcsf
shown
enhanc
immun
tumor
stimul
antitumor
activ
human
cell
better
ndv
vector
alon
jank
et
al
recombin
ndv
vector
express
reduc
tumor
volum
caus
higher
remiss
rate
colon
carcinoma
tumor
mice
compar
ndv
alon
vigil
et
al
new
approach
involv
express
tumorrel
antibodi
ndv
genom
also
promis
cancer
therapi
puhler
et
al
addit
safeti
ndv
alreadi
demonstr
human
freeman
et
al
lauri
et
al
thu
ndv
show
promis
valuabl
recombin
vector
human
bird
vesicular
stomat
viru
vsv
contain
nonseg
singlestrand
negativesens
rna
genom
belong
famili
rhabdovirida
vsv
genom
organ
similarli
ndv
except
vsv
encod
protein
respons
fusion
attach
glycoprotein
g
wherea
ndv
encod
two
separ
protein
function
f
hn
vsv
normal
infect
hors
cattl
swine
caus
vesicular
lesion
mouth
nose
teat
hoov
infect
usual
clear
within
two
week
without
complic
natur
vsv
spread
primarili
arthropod
vector
sand
fli
lutzomyia
shannoni
black
fli
simulium
vittatum
though
transmiss
animaltoanim
contact
report
letchworth
et
al
stallknecht
et
al
rodriguez
vsv
consid
good
vaccin
vector
candid
sinc
human
preexist
antibodi
would
interfer
induct
immun
respons
foreign
protein
express
viru
recombin
vsv
express
ha
wsn
influenza
viru
strain
rescu
subsequ
shown
confer
protect
mice
challeng
wsn
viru
kretzschmar
et
al
robert
et
al
vsv
express
ha
ahong
highli
pathogen
viru
shown
elicit
neutral
antibodi
mice
confer
protect
challeng
ahong
viru
fig
interestingli
recombin
vector
induc
crossreact
neutral
antibodi
distantli
relat
virus
longterm
protect
also
achiev
vector
mice
fulli
protect
month
vaccin
challeng
schwartz
et
al
experi
demonstr
vsv
may
suitabl
recombin
vector
influenza
viru
ha
protein
recombin
vsv
vector
express
variou
viral
bacteri
protein
pathogen
also
test
anim
model
vsv
vector
express
yersinia
pesti
lcrv
gene
provid
protect
mice
lethal
pulmonari
challeng
yersinia
pesti
palin
et
al
vaccin
recombin
vsv
express
sar
spike
protein
provid
protect
challeng
sar
young
age
mice
kapadia
et
al
vogel
et
al
vsv
vector
also
current
test
vaccin
therapeut
agent
hiv
johnson
et
al
schnell
et
al
haglund
et
al
rose
et
al
ramsburg
et
al
publicov
et
al
okuma
et
al
cooper
et
al
recombin
vsv
vector
develop
mani
virus
herp
simplex
viru
type
borna
diseas
viru
marburg
viru
papillomavirus
daddariodicaprio
et
al
natuk
et
al
brandsma
et
al
b
perez
et
al
one
limit
vsv
recombin
vector
appear
caus
pathogen
human
though
human
rare
infect
anim
handler
expos
vsv
show
symptom
diseas
rang
asymptomat
fever
myalgia
resolv
within
week
mous
studi
vsv
infect
demonstr
viru
replic
olfactori
nerv
soon
intranas
infect
cross
barrier
viru
spread
mani
area
brain
result
neuropatholog
hindlimb
paralysi
death
huneycutt
et
al
bi
et
al
plakhov
et
al
vsv
infect
also
analyz
nonhuman
primat
critic
determin
safeti
vector
model
prior
human
use
macaqu
inocul
vsv
intranas
shed
viru
nasal
wash
first
day
infect
viru
caus
viremia
enter
central
nervou
system
howev
macaqu
inject
vsv
directli
brain
intrathalam
inject
viru
spread
caus
sever
diseas
symptom
johnson
et
al
order
vsv
use
recombin
vector
human
viru
must
attenu
diseas
symptom
elimin
fortun
much
alreadi
discov
mechan
vsv
pathogen
attenu
vsv
vector
ration
design
insert
hiv
gag
protein
vsv
genom
attenu
viru
suffici
caus
pathogenesi
macaqu
though
addit
viral
attenu
may
necessari
human
trial
johnson
et
al
truncat
cytoplasm
region
g
protein
shown
attenu
vsv
growth
pathogenesi
mice
robert
et
al
recombin
vector
contain
g
protein
delet
express
hiv
env
protein
elicit
cell
respons
compar
wtvsv
express
env
protein
publicov
et
al
anoth
strategi
attenu
vsv
express
hiv
protein
includ
place
gag
begin
genom
result
reduct
express
vsv
protein
reduct
viral
replic
also
n
gene
move
downstream
posit
reduc
n
protein
express
viral
replic
protein
shown
inhibit
interferon
respons
induc
apoptosi
also
mutat
reduc
vsv
pathogenesi
clark
et
al
cooper
et
al
appli
combin
alter
recombin
vsv
vector
express
gag
protein
result
drastic
reduct
pathogenesi
mice
still
induc
strong
immun
respons
gag
cooper
et
al
vsv
vector
replic
pathogenesi
also
elimin
use
vsv
mutant
complet
one
cycl
replic
achiev
elimin
vsv
g
protein
genom
sinc
vsv
g
protein
g
gene
necessari
viral
growth
vector
grown
readili
cell
line
constitut
express
vsv
g
g
protein
incorpor
viral
envelop
anim
singlecycl
vsv
vector
enter
infect
cell
express
viral
foreign
protein
genom
viral
assembl
occur
g
protein
synthes
vsv
singlecycl
vector
express
hiv
env
demonstr
produc
immun
respons
env
similar
respons
elicit
replic
vsv
vector
express
env
publicov
et
al
vsv
vector
attenu
mutat
investig
care
safe
administ
human
without
side
effect
similar
ndv
vsv
also
analyz
therapeut
cancer
agent
base
observ
vsv
replic
induc
apoptosi
cancer
cell
readili
normal
cell
barber
vsv
also
sensit
effect
interferon
tumor
cell
without
intact
interferon
pathway
rapidli
kill
vsv
vsv
vector
express
cytokin
chemokin
inhibitor
equin
herp
glycoprotein
abl
enhanc
tumor
reduct
squamou
cell
carcinoma
hepatocellular
carcinoma
respect
mice
shin
et
al
altomont
et
al
thu
vsv
vector
show
potenti
function
vaccin
infecti
diseas
well
cancer
recent
interest
use
influenza
viru
recombin
vector
protect
highli
virul
influenza
viru
strain
well
pathogen
influenza
virus
need
highli
attenu
use
vector
sever
strategi
attenu
influenza
virus
success
attenu
coldadapt
strain
gener
grow
influenza
viru
primari
chick
kidney
cell
current
licens
use
human
cox
et
al
attenu
coldadapt
strain
gener
embryon
chicken
egg
grown
low
temperatur
also
use
hors
youngner
et
al
reduct
virul
also
observ
influenza
virus
contain
delet
protein
viral
protein
respons
inhibit
innat
interferon
respons
garciasastr
et
al
talon
et
al
influenza
viru
vaccin
contain
delet
gene
necessari
viru
uncoat
current
test
watanab
et
al
thu
like
mani
way
suffici
attenu
influenza
viru
sever
influenza
viru
vector
shown
promis
result
anim
model
recombin
influenza
viru
contain
ndv
hn
ectodomain
place
influenza
viru
na
ectodomain
administ
ovo
provid
protect
chicken
influenza
viru
ndv
lethal
challeng
fig
steel
et
al
million
peopl
die
year
infect
mycobacterium
tuberculosi
effect
vaccin
urgent
need
vaccin
influenza
viru
express
truncat
protein
protein
mycobacterium
tuberculosi
ns
gene
segment
provid
protect
mice
guinea
pig
lethal
challeng
bacteria
sereinig
et
al
stukova
et
al
recombin
influenza
virus
express
portion
bacillu
anthraci
protein
fuse
influenza
viru
ha
protein
elicit
antibodi
bacillu
anthraci
influenza
viru
li
et
al
protect
mice
achiev
vaccin
influenza
viru
express
chlamydia
trachomati
epitop
na
protein
et
al
mice
vaccin
influenza
viru
express
epitop
pseudomona
aeruginosa
lead
caus
mortal
cystic
fibrosi
patient
fulli
protect
challeng
gilleland
et
al
chimer
influenza
virus
develop
express
hiv
epitop
intranas
administr
vector
induc
longlast
mucos
antibodi
respons
respiratori
tract
also
genit
tract
li
et
al
muster
et
al
pales
et
al
gonzalo
et
al
gherardi
et
al
nakaya
et
al
encourag
result
obtain
use
influenza
viru
vector
thu
far
demonstr
need
research
field
live
coldadapt
influenza
viru
vaccin
success
administ
million
individu
safeti
must
care
consid
develop
futur
liveattenu
influenza
viru
vaccin
liveattenu
influenza
viru
vaccin
must
design
pathogen
viru
could
result
reassort
vaccin
circul
influenza
viru
strain
issu
address
coldadapt
vaccin
demonstr
three
intern
gene
contain
attenu
mutat
make
unlik
reassort
would
lead
virul
viral
strain
cox
et
al
jin
et
al
issu
vectormedi
immun
concern
live
vaccin
influenza
viru
rapidli
evolv
due
antigen
drift
liveattenu
influenza
viru
vaccin
like
coldadapt
vaccin
must
reformul
year
reflect
newli
emerg
strain
peopl
infect
multipl
time
differ
strain
influenza
viru
recombin
vector
base
influenza
viru
could
repeatedli
administ
design
use
differ
antigen
variant
influenza
viru
adenovirus
nonenvelop
dna
virus
thoroughli
explor
potenti
use
recombin
vaccin
vector
adenovirus
origin
identifi
one
caus
acut
respiratori
infect
infect
adenovirus
also
associ
conjunct
gastroenter
infant
adenoviru
infect
usual
result
mild
diseas
symptom
promptli
resolv
adenoviru
infect
immunocompromis
individu
result
sever
diseas
symptom
pneumonia
enceph
even
death
krilov
adenoviru
often
chosen
recombin
vaccin
vector
express
foreign
protein
live
vaccin
administ
us
militari
person
two
decad
incid
signific
side
effect
souza
et
al
oral
vaccin
consist
two
preval
strain
adenoviru
among
militari
person
contain
capsul
coat
prevent
releas
virus
reach
intestin
howel
et
al
lichtenstein
wold
potenti
caus
ill
mani
adenoviru
vector
current
develop
test
replic
defect
spread
celltocel
replicationdefect
vector
often
delet
portion
viral
genom
sinc
region
necessari
initi
viral
replic
souza
et
al
addit
extens
record
militari
vaccin
adenoviru
offer
sever
advantag
recombin
vaccin
vector
viral
genom
rel
easi
manipul
viru
grow
high
titer
adenoviru
lyophil
need
refriger
souza
et
al
reason
adenoviru
one
popular
recombin
vector
pharmaceut
compani
chosen
test
adenoviru
vector
clinic
trial
sever
group
demonstr
recombin
adenoviru
vector
express
influenza
viru
protein
protect
anim
challeng
adenoviru
vector
express
ha
np
swine
influenza
viru
fulli
protect
swine
lethal
challeng
wesley
et
al
recombin
adenoviru
vector
express
ha
hpai
induc
cellular
humor
immun
mice
vaccin
complet
protect
mice
chicken
lethal
challeng
gao
et
al
adenoviru
vector
express
ha
strain
use
vaccin
chicken
ovo
provid
complet
protect
lethal
challeng
strain
partial
protect
strain
toro
et
al
longlast
immun
vaccin
adenoviru
vector
express
ha
viru
provid
protect
lethal
challeng
least
one
year
hoelscher
et
al
adenoviru
vector
current
examin
possibl
vaccin
varieti
virus
adenoviru
vector
shown
prevent
diseas
challeng
includ
express
herp
simplex
viru
measl
viru
h
n
f
protein
mcdermott
et
al
fook
et
al
sharp
et
al
perhap
famou
adenoviru
vector
mercksponsor
hiv
vaccin
recent
went
clinic
trial
vaccin
consist
adenoviru
vector
contain
hiv
nef
gag
pol
gene
steinbrook
sekali
vaccin
administ
three
inject
zero
two
six
month
clinic
trial
halt
earli
becam
clear
vaccin
fail
prevent
hiv
infect
individu
given
vaccin
also
higher
rate
hiv
infect
given
placebo
sekali
devast
failur
necessit
thorough
analysi
went
wrong
repeat
futur
trial
clear
major
problem
mani
peopl
expos
strain
use
vaccin
vector
half
individu
western
countri
antibodi
peopl
develop
countri
antibodi
presenc
preexist
antibodi
like
led
rapid
memori
immun
respons
prevent
develop
immun
respons
hiv
protein
express
vector
unexpect
yet
fulli
explain
individu
previous
expos
adenoviru
vaccin
suscept
hiv
infect
research
test
less
common
strain
adenoviru
use
vector
hope
circumv
preexist
immun
problem
hofmann
et
al
reddi
et
al
farina
et
al
surprisingli
first
time
adenoviru
vector
unexpectedli
harm
clinic
trial
particip
adenoviru
vector
use
gene
therapi
trial
well
therapi
cancer
gene
therapi
trial
particip
die
inflammatori
respons
receiv
high
dose
vector
viru
particl
lehrman
marshal
anoth
disadvantag
use
vector
adenoviru
genom
dna
risk
viral
dna
may
disrupt
host
gene
possibl
caus
cancer
adenoviru
strain
caus
cancer
laboratori
anim
trentin
et
al
even
though
adenovirus
shown
caus
human
cancer
possibl
cancer
case
may
aris
vaccin
larg
popul
light
fiasco
involv
vector
difficult
forese
high
enthusiasm
adenoviru
vector
futur
vector
seem
promis
venezuelan
equin
enceph
viru
vee
rna
viru
primarili
infect
equin
central
south
america
contrast
adenoviru
human
preexist
antibodi
vee
could
interfer
vaccin
davi
et
al
like
vsv
vee
transmit
insect
strain
vee
rang
pathogen
avirul
caus
acut
enceph
death
equin
human
infect
well
usual
develop
mild
symptom
human
death
occur
weaver
et
al
thu
vee
must
highli
attenu
order
use
vaccin
vector
mani
vee
vaccin
test
use
viral
replicon
particl
vrp
capabl
infect
cell
spread
throughout
host
foreign
protein
express
high
level
vrp
vector
one
major
advantag
use
vector
vee
target
antigenpres
cell
drain
lymph
node
foreign
antigen
present
directli
site
adapt
immun
respons
begin
davi
et
al
charl
et
al
anoth
advantag
vee
vaccin
also
induc
iga
mucos
immun
respons
even
subcutan
inject
vaccin
charl
et
al
sinc
mani
pathogen
includ
hiv
initi
invad
mucos
surfac
induct
mucos
immun
vaccin
highli
desir
vee
vrp
express
ha
influenza
viru
use
success
protect
twoweekold
chicken
lethal
challeng
fig
schultzcherri
et
al
vee
vaccin
also
develop
mani
agent
includ
siv
hiv
lassa
viru
norwalk
viru
borrelia
burgdorferi
caus
agent
lyme
diseas
sarscov
cowpox
viru
dengu
viru
rsv
caley
et
al
pushko
et
al
davi
et
al
baric
et
al
harrington
et
al
gipson
et
al
johnston
et
al
deme
et
al
cecil
et
al
mok
et
al
thornburg
et
al
white
et
al
test
determin
whether
vee
vaccin
vector
safe
efficaci
human
poxvirus
dna
virus
larg
genom
studi
recombin
vector
success
erad
smallpox
use
vaccinia
viru
vaccinia
virus
possess
sever
properti
ideal
vector
panicali
et
al
easi
inexpens
manufactur
lyophil
accommod
larg
insert
foreign
dna
induc
mucos
system
immun
oral
administr
gherardi
esteban
souza
et
al
major
drawback
vaccinia
vector
larg
segment
popul
preexist
immun
vaccinia
smallpox
erad
program
would
interfer
induct
immun
respons
foreign
protein
express
vaccinia
viru
overcom
similar
poxvirus
speci
crossreact
vaccinia
viru
canarypox
viru
fowlpox
viru
current
test
johnson
et
al
bublot
et
al
howev
appear
recombin
vector
induc
weaker
immun
respons
foreign
protein
compar
recombin
vaccinia
vector
zhang
et
al
canarypox
vaccin
encod
hiv
fail
phase
clinic
trial
human
sinc
fail
elicit
strong
cellular
immun
respons
russel
et
al
also
vaccine
spread
vaccinia
viru
individu
especi
danger
immunocompromis
individu
address
replicationdefect
attenu
vaccinia
virus
ankara
strain
evalu
recombin
vector
potenti
though
attenu
strain
crossreact
vaccinia
viru
make
less
like
ultim
success
souza
et
al
anoth
strategi
involv
alter
current
licens
live
attenu
measl
viru
express
foreign
protein
hope
would
strong
immun
respons
measl
viru
foreign
protein
zuniga
et
al
measl
viru
vaccin
highli
efficaci
infant
excel
safeti
record
measl
viru
vector
express
west
nile
viru
glycoprotein
protect
mice
lethal
challeng
west
nile
viru
despr
et
al
disadvantag
vector
human
popul
alreadi
vaccin
preexist
immun
measl
viru
howev
mice
macaqu
vaccin
measl
viru
vaccin
month
vaccin
measl
viru
vaccin
express
hiv
anim
develop
antibodi
titer
hiv
similar
antibodi
titer
anim
lorin
et
al
work
requir
substanti
result
order
recommend
use
vector
human
preexist
measl
viru
immun
least
promis
method
vaccin
infant
measl
viru
anoth
pathogen
current
vaccin
strategi
develop
use
bacteria
deliveri
vehicl
foreign
antigen
attenu
strain
intracellular
bacteria
salmonella
enterica
serovar
typhimurium
listeria
monocytogen
engin
recombin
vector
schoen
et
al
cheminay
hensel
schoen
et
al
intracellular
bacteria
remain
membranebound
vesicl
insid
host
cell
prevent
foreign
protein
express
bacteria
enter
host
cytosol
necessari
step
antigen
present
immun
system
two
mechan
antigen
deliveri
combat
problem
test
bacteri
vector
one
involv
synthesi
foreign
protein
insid
bacteria
releas
foreign
protein
human
cell
bacteri
type
iii
secretori
pathway
panthel
et
al
protein
must
unfold
prior
secret
foreign
protein
high
stabil
complet
unfold
unabl
exit
bacteri
cell
demonstr
remov
small
stabil
domain
hiv
protein
allow
larg
foreign
protein
secret
type
iii
pathway
chen
et
al
howev
complex
bacteri
genom
difficulti
secret
foreign
protein
limit
use
system
anoth
mechan
antigen
deliveri
bacteri
vector
involv
releas
dna
encod
foreign
protein
host
cell
essenti
dna
vaccin
deliv
live
bacteri
organ
strategi
includ
transform
bacteria
nake
dna
vector
encod
foreign
gene
bacteria
target
antigenpres
cell
listeria
monocytogen
target
dendrit
cell
must
use
techniqu
chosen
bacteria
highli
attenu
design
lyse
upon
host
cell
entri
bacteria
lyse
dna
vector
enter
cytosol
transport
nucleu
transcrib
translat
cytoplasm
antigen
process
present
mhc
mhc
ii
molecul
order
stimul
humor
cellular
immun
mollenkopf
et
al
weiss
schoen
et
al
method
show
promis
viral
vector
preexist
immun
bacteri
vector
appear
inhibit
product
immun
respons
foreign
protein
sevil
domenech
et
al
new
area
recombin
vector
research
focus
use
transgen
plant
deliveri
vector
plant
safe
inexpens
vector
easili
grown
larg
quantiti
stabl
room
temperatur
design
express
mani
antigen
webster
et
al
express
hiv
antigen
plant
report
vaccin
vector
current
evalu
efficaci
yusibov
et
al
marus
et
al
grow
interest
use
recombin
vector
vaccin
influenza
viru
danger
pathogen
reflect
realiti
vaccin
substanti
advantag
type
vaccin
recombin
vector
appear
encourag
other
ideal
hope
sever
differ
vector
ultim
use
vaccin
differ
diseas
import
hurdl
overcom
develop
recombin
vector
problem
preexist
immun
mani
vector
test
issu
preexist
immun
must
also
address
recombin
virus
human
current
immun
peopl
vaccin
multipl
time
influenza
viru
viral
ha
protein
mutat
strong
immun
respons
gener
vector
first
vaccin
vector
may
abl
replic
suffici
success
administr
would
prevent
format
immun
respons
mutat
leav
individu
vulner
infect
alter
influenza
virus
address
vsv
gener
vector
express
differ
serotyp
vsv
g
protein
crossreact
recombin
vsv
vector
express
hiv
env
elicit
strong
immun
respons
env
subsequ
vaccin
differ
vsv
vector
express
hiv
env
g
protein
use
boost
initi
immun
respons
rose
et
al
work
area
need
overcom
limit
recombin
vector
comparison
viral
vector
shown
tabl
overal
recombin
vector
provid
safe
effect
mechan
elicit
humor
cellular
immun
danger
pathogen
planet
